Immune thrombocytopenia an autoimmune disease known for having decreased platelets count which in turn results in frequent bruising & bleeding due to loss of clot formation ability. Patients usually struggle finding an effective treatment gladly FDA just recently approved new treatment Wayrilz.

Patients with Chronic immune thrombocytopenia (ITP) in patients who have not achieved adequate response to immunoglobulins, anti-D therapy, or corticosteroids. Now have new hope with Wayrliz.

The safety and effectiveness of Wayrilz were assessed in a 24-week, double-blind study comparing it to placebo, with the primary focus on achieving a durable platelet response (an increase in platelet count maintained for most of the final 12 weeks). A total of 202 patients participated, with 133 receiving Wayrilz and 69 receiving placebo. By the end of the study, 31 patients (23%) in the Wayrilz group achieved a sustained platelet response, while no patients in the placebo group did.

Wayrilz may increase the risk of serious bacterial, viral, or fungal infections. The most common side effects include diarrhea, nausea, headache, abdominal pain, and COVID-19. The recommended dose is 400 mg orally twice daily, taken whole with water. To reduce gastrointestinal symptoms, patients may take Wayrilz with food. Tablets should not be cut, crushed, or chewed.

Learn more:  FDA Approves Drug to Treat Adults with Persistent or Chronic Immune Thrombocytopenia